Oral Long-Acting PTH
Hypoparathyroidism
Discovery/PreclinicalActive; Co-development with OPKO (Feb 2026)
Key Facts
Indication
Hypoparathyroidism
Phase
Discovery/Preclinical
Status
Active; Co-development with OPKO (Feb 2026)
Company
About Entera Bio
Entera Bio is a clinical-stage biotech focused on transforming injectable peptide therapies into convenient oral tablets using its proprietary N-Tab® drug delivery platform. The company's strategy de-risks development by targeting well-characterized peptides like PTH, with its lead asset, EB613 for osteoporosis, having completed a positive Phase 2 study and a streamlined Phase 3 protocol submitted in early 2026. Backed by a seasoned management team and strategic partnerships, Entera aims to redefine standards of care by improving patient adherence and enabling earlier therapeutic intervention.
View full company profileOther Hypoparathyroidism Drugs
| Drug | Company | Phase |
|---|---|---|
| EB-612 | Extend Biosciences | Phase 2 |
| Hypoparathyroidism Program | Confo Therapeutics | Discovery |
| Oral Long-Acting PTH Tablet | Opko Health | Pre-clinical/Phase 1 |
| Canvuparatide (MBX 2109) | MBX Biosciences | Phase 2 |
| SEP-479 (PTH1R) | Septerna | Phase 2 |
| EB612 (oral PTH(1-34)) | Entera Bio | Phase 2 |